The company's second quarter revenue growth was driven in part by strong sales from its life science segment.
The studies provide further support for Meridian's Illumigene Malaria as a tool for routine screening of travelers in non-endemic areas of the world.
The firm has launched a line of 60 rapid immunoassays aimed at emerging markets, and plans to emphasize its menu to drive uptake of its molecular platform.
The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
The firm provided updated guidance for the year, which also fell below analysts' estimates, and cut its annual indicated dividend rate.
Executives from Genomic Health, Meridian Bioscience, and Qiagen provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.
By detecting as little as one parasite per microliter of whole blood, the test could be used to further future efforts aimed at malaria eradication.
The results affirmed the company's preliminary earnings issued last month.
The company said it expects a 1 percent increase in 2016 revenues, but noted that the results were adversely affected by certain competitive pressures in Q4, among other problems.
The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.